Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”
A "safety signal" detected during Genentech's Phase III trial of Tarceva (erlotinib) for first-line combination therapy in non-small cell lung cancer will not impact the rest of the agent's development program, the company said April 9
You may also be interested in...
FDA will take regulatory action on AstraZeneca's Iressa (gefitinib) by May 5
AstraZeneca believes a controlled, cross-over trial could be used to confirm the sympom benefit of Iressa in refractory non-small cell lung cancer patients, VP-Medical Director of Oncology George Blackledge, MD, said during FDA's Oncologic Drugs Advisory Committee Sept. 24
Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.